Bank Pictet & Cie Europe AG Grows Holdings in Moderna, Inc. $MRNA

Key Points

• Bank Pictet & Cie Europe AG increased its stake in Moderna by 38.5% in Q2, owning approximately 0.19% of the company, valued at $20.2 million.
• Moderna's stock opened at $24.61, with a market capitalization of $9.58 billion, a price-to-earnings ratio of -3.27, and significant fluctuations over the past year.
• Analysts have mixed ratings on Moderna, with a consensus rating of "Hold" and an average price target of $41.81, reflecting varying confidence in its future performance.

Bank Pictet & Cie Europe AG lifted its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 38.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 733,686 shares of the company's stock after buying an additional 204,000 shares during the quarter. Bank Pictet & Cie Europe AG owned approximately 0.19% of Moderna worth $20,242,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. S Bank Fund Management Ltd acquired a new position in Moderna during the 1st quarter worth $25,000. TD Private Client Wealth LLC lifted its position in shares of Moderna by 348.8% during the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company's stock worth $26,000 after purchasing an additional 743 shares during the last quarter. SVB Wealth LLC acquired a new position in Moderna in the first quarter worth about $28,000. CX Institutional increased its holdings in Moderna by 1,129.8% in the second quarter. CX Institutional now owns 1,033 shares of the company's stock valued at $29,000 after buying an additional 949 shares during the last quarter. Finally, Costello Asset Management INC acquired a new stake in Moderna during the first quarter valued at approximately $30,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Stock Performance

MRNA stock opened at $24.61 on Friday. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $67.96. The stock has a market capitalization of $9.58 billion, a price-to-earnings ratio of -3.27 and a beta of 1.93. The stock's fifty day moving average is $27.05 and its two-hundred day moving average is $27.73.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings data on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The business had revenue of $142.00 million for the quarter, compared to analysts' expectations of $116.26 million. During the same quarter last year, the company earned ($3.33) EPS. The company's revenue for the quarter was down 41.1% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. As a group, analysts predict that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on MRNA shares. JPMorgan Chase & Co. set a $26.00 target price on Moderna in a research report on Friday, August 1st. Bank of America decreased their price objective on shares of Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a report on Tuesday, July 22nd. Wells Fargo & Company reiterated an "equal weight" rating on shares of Moderna in a research note on Sunday, July 13th. Evercore ISI set a $32.00 price target on shares of Moderna in a research report on Friday, August 1st. Finally, Leerink Partners decreased their price target on shares of Moderna from $18.00 to $15.00 and set an "underperform" rating for the company in a report on Friday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, fourteen have issued a Hold rating and four have issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $41.81.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.